Qualified Health vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
Enterprise AI for health systems; raised $125M Series B (NEA + Anthropic fund, March 2026); 500K+ users; AI agents covering ~7% of US hospital revenue; integrates with existing EHR systems
About
Qualified Health is an enterprise AI company building intelligent systems for large health systems and hospital networks. Founded to address the complexity of clinical and operational decision-making in healthcare, the company develops AI agents that assist clinicians, administrators, and care teams with data-intensive workflows. Its platform is designed to integrate with existing electronic health record systems and enterprise infrastructure, enabling health systems to deploy AI without replacing legacy technology.\n\nThe company targets enterprise health systems — specifically the largest hospital networks in the United States — with AI tools that span clinical decision support, administrative automation, and patient engagement. Qualified Health emphasizes safety, compliance, and interpretability in its models, which is critical for adoption in regulated healthcare settings. The platform is built to handle the scale and data sensitivity requirements of organizations managing hundreds of thousands of patients.\n\nQualified Health raised a $125M Series B led by NEA and backed by the Anthropic fund, signaling strong confidence from both traditional healthcare investors and AI-native institutional backers. The company has grown to 500,000+ users and its platform now touches approximately 7% of total US hospital revenue — a remarkable reach for a relatively young company. As of early 2026, Qualified Health is one of the best-capitalized enterprise health AI startups in the market.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.